IXC chart, page-345

So, Sophie Alice Loverage. Daughter of Jason I understand.
Sitting in top 20.
I realise this has been mentioned before, but this is quite bullish. It’s one thing for an established biotech investor / ceo to have skin in the game. It’s quite another for your daughter to invest also. I presume they talk and discuss ect (generics, not insider info). Probably speaks to the conviction of management in their asset.
Tom has previously said they have high conviction in presendin - though he hasn’t mentioned that for a little while. Sure that view has not changed behind the scenes.

Feel free to give alternate views, I may have anchor / conviction bias myself.